Ana Pena, PhD,  —

Using antibiotics may increase the risk of developing amyotrophic lateral sclerosis (ALS), with a higher number of prescriptions linked to greater risk, a nationwide study in Sweden suggests.  However, the researchers caution that more studies are needed to prove a direct,…

Biogen’s investigational therapy tofersen can significantly reduce toxic levels of SOD1 protein and may slow disability progression in people with familial amyotrophic lateral sclerosis (ALS) caused by SOD1 mutations, interim study results show. The positive data from a Phase 1/2 clinical trial support advancing the experimental compound into Phase 3…

Project ALS and Columbia University are launching a new platform with a goal of discovering more useful treatments for amyotrophic lateral sclerosis (ALS) patients, and pushing the most promising candidates to clinical trials. Core, as it…

Aquestive’s new drug application for Exservan — an investigational oral film of riluzole to be used as an add-on therapy for amyotrophic lateral sclerosis (ALS) — has been accepted by the U.S. Food…

Mitsubishi Tanabe Pharma America (MTPA), in collaboration with the Massachusetts General Hospital (MGH), is conducting a study to identify biomarkers related to amyotrophic lateral sclerosis (ALS), which may be helpful to measure patient response to Radicava (edaravone). The study will be sponsored by MTPA, Radicava’s seller in…

A model of motor neuron disease based on patient-derived stem cells won the 2018 International 3Rs Prize for its potential to lessen or replace the use of animals as models in amyotrophic lateral sclerosis (ALS) research. The prize, given by the National Center for the 3Rs (NC3Rs) and sponsored by …

Amylyx has completed patient recruitment for the Phase 2 clinical trial CENTAUR, which addresses the safety and effectiveness of AMX0035 as an oral treatment for amyotrophic lateral sclerosis (ALS). In 2017, Amylyx launched…

Examining the genetic risk for amyotrophic lateral sclerosis (ALS) may become a lot easier with a user-friendly tool called ALSgeneScanner, which is meant to be used by non-specialists such as health care professionals and patients. The method is able to analyze DNA sequencing data from patients and distinguish…

Treatment with ultra-high-dose methylcobalamin, the physiologically active form of vitamin B12, may improve the prognosis of patients with amyotrophic lateral sclerosis (ALS) who receive it a year or less after symptom onset, a…

EnClear Therapies, a biotech company developing a device to halt the progression of neurological diseases including amyotrophic lateral sclerosis (ALS), announced it has spun out from QurAlis, one of its founding companies.